UK markets closed

Dr. Reddy's Laboratories Limited (RDY)

NYSE - Nasdaq Real-time price. Currency in USD
Add to watchlist
71.75-0.40 (-0.55%)
As of 02:29PM EDT. Market open.

Dr. Reddy's Laboratories Limited

8-2-337, Road No. 3
Banjara Hills
Hyderabad 500034
India
91 40 4900 2900
https://www.drreddys.com

Sector(s)Healthcare
IndustryDrug Manufacturers - Specialty & Generic
Full-time employees25,863

Key executives

NameTitlePayExercisedYear born
Mr. Gunupati Venkateswara Prasad B.E.Co-Chairman, MD & Member of Management Council2.25MN/A1960
Mr. Kallam Satish Reddy B.Tech., M.S.Chairman of the Board & Member of the Management Council1.38MN/A1967
Mr. Erez Israeli M.B.A.CEO & Member of the Management CouncilN/AN/A1968
Mr. Parag AgarwalCFO & Member of Management CouncilN/AN/A1967
Mr. Deepak Sapra M.B.A.CEO of API & Services & Member of Management CouncilN/AN/A1975
Mr. Venkata Ramana Motupalli M.B.A.CEO of Branded Markets - India & Emerging Countries and Member of Management CouncilN/AN/A1969
Ms. Archana Bhaskar B.Sc., M.B.A.EVP, Head of Corporate Communications, Chief Human Resources Officer & Member of Management CouncilN/AN/A1967
Mr. Sanjay Sharma B.Tech.Executive VP, Global Head of Global Manufacturing & Member of Management CouncilN/AN/A1968
Mr. Marc Kikuchi B.A., M.B.A.CEO of North America Generics & Member of Management CouncilN/AN/A1969
Mr. Patrick Aghanian B.A., M.B.A.CEO of European Generics & Member of Management CouncilN/AN/A1965
Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations. This segment also engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.

Corporate governance

Dr. Reddy's Laboratories Limited’s ISS governance QualityScore as of 1 April 2024 is 4. The pillar scores are Audit: 6; Board: 3; Shareholder rights: 1; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.